KR20210122803A - 항체 전하 이질성의 고유 마이크로유체 ce-ms 분석 - Google Patents
항체 전하 이질성의 고유 마이크로유체 ce-ms 분석 Download PDFInfo
- Publication number
- KR20210122803A KR20210122803A KR1020217026598A KR20217026598A KR20210122803A KR 20210122803 A KR20210122803 A KR 20210122803A KR 1020217026598 A KR1020217026598 A KR 1020217026598A KR 20217026598 A KR20217026598 A KR 20217026598A KR 20210122803 A KR20210122803 A KR 20210122803A
- Authority
- KR
- South Korea
- Prior art keywords
- antibody
- interest
- sample
- post
- charge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000004458 analytical method Methods 0.000 title claims description 20
- 238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 title description 23
- 238000000034 method Methods 0.000 claims abstract description 132
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 52
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 52
- 238000005251 capillar electrophoresis Methods 0.000 claims abstract description 22
- 108091005804 Peptidases Proteins 0.000 claims abstract description 14
- 239000004365 Protease Substances 0.000 claims abstract description 14
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 11
- 230000001323 posttranslational effect Effects 0.000 claims abstract description 8
- 238000010183 spectrum analysis Methods 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 238000000926 separation method Methods 0.000 claims description 34
- 230000004481 post-translational protein modification Effects 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 23
- 239000011159 matrix material Substances 0.000 claims description 20
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 10
- 239000000611 antibody drug conjugate Substances 0.000 claims description 9
- 230000013595 glycosylation Effects 0.000 claims description 8
- 238000006206 glycosylation reaction Methods 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 7
- 238000012510 peptide mapping method Methods 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 230000006240 deamidation Effects 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 5
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 5
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 229940043131 pyroglutamate Drugs 0.000 claims description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 3
- 238000013507 mapping Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 72
- 239000012634 fragment Substances 0.000 description 37
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 32
- 150000002500 ions Chemical class 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 15
- 238000004949 mass spectrometry Methods 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 239000000499 gel Substances 0.000 description 12
- 238000000132 electrospray ionisation Methods 0.000 description 11
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 238000004255 ion exchange chromatography Methods 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000004885 tandem mass spectrometry Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 238000011154 charge variant analysis Methods 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000001360 collision-induced dissociation Methods 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000005040 ion trap Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 239000003398 denaturant Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000012437 strong cation exchange chromatography Methods 0.000 description 3
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000012494 forced degradation Methods 0.000 description 2
- 238000012495 forced degradation study Methods 0.000 description 2
- 239000005350 fused silica glass Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 150000002669 lysines Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710127332 Protease I Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002090 nanochannel Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 238000005173 quadrupole mass spectroscopy Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000001518 sector field mass spectrometry Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000002150 sonic spray mass spectrometry Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001920 surface-enhanced laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4044—Concentrating samples by chemical techniques; Digestion; Chemical decomposition
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962799331P | 2019-01-31 | 2019-01-31 | |
| US62/799,331 | 2019-01-31 | ||
| US201962851365P | 2019-05-22 | 2019-05-22 | |
| US62/851,365 | 2019-05-22 | ||
| PCT/US2020/015875 WO2020160266A1 (en) | 2019-01-31 | 2020-01-30 | Native microfluidic ce-ms analysis of antibody charge heterogeneity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210122803A true KR20210122803A (ko) | 2021-10-12 |
Family
ID=69811860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217026598A Withdrawn KR20210122803A (ko) | 2019-01-31 | 2020-01-30 | 항체 전하 이질성의 고유 마이크로유체 ce-ms 분석 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12169203B2 (https=) |
| EP (1) | EP3918339A1 (https=) |
| JP (1) | JP2022519246A (https=) |
| KR (1) | KR20210122803A (https=) |
| CN (1) | CN113646638B (https=) |
| AU (1) | AU2020216172A1 (https=) |
| BR (1) | BR112021013716A2 (https=) |
| CA (1) | CA3126712A1 (https=) |
| IL (1) | IL284929A (https=) |
| MX (1) | MX2021009267A (https=) |
| SG (1) | SG11202108033TA (https=) |
| WO (1) | WO2020160266A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114544839B (zh) * | 2022-01-20 | 2024-08-20 | 未名生物医药有限公司 | 一种抗人神经生长因子抗体的电荷变异体检测方法 |
| KR20240164561A (ko) * | 2022-03-18 | 2024-11-19 | 리제너론 파아마슈티컬스, 인크. | 폴리펩타이드 변종을 분석하기 위한 방법 및 시스템 |
| WO2024020199A1 (en) * | 2022-07-21 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Native microfluidic ce-ms analysis of antibody charge heterogeneity |
| WO2025022284A1 (en) * | 2023-07-25 | 2025-01-30 | Dh Technologies Development Pte. Ltd. | Method for in-capillary dissociation and analysis of mass spectral data |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2370749A1 (en) * | 1999-04-20 | 2000-10-26 | Target Discovery, Inc. | Polypeptide fingerprinting methods, metabolic profiling, and bioinformatics database |
| FR2862134B1 (fr) * | 2003-11-12 | 2007-07-27 | Sebia Sa | Analyse et typage de proteines monoclonales par electrophorese capillaire et immunodeplacement |
| CN101201355A (zh) * | 2006-12-15 | 2008-06-18 | 许洋 | 免疫组质谱检测个体化肿瘤生物标志及疗效试剂盒和方法 |
| US20100187113A1 (en) * | 2009-01-26 | 2010-07-29 | Vladislav Dolnik | Capillary sieving electrophoresis with a cationic surfactant for size separation of proteins |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| CN103033628A (zh) * | 2012-12-18 | 2013-04-10 | 北京科技大学 | 制备个体全蛋白质组芯片的方法及其应用 |
| EP3885368A1 (en) * | 2015-05-12 | 2021-09-29 | Regeneron Pharmaceuticals, Inc. | Multimeric protein purity determination |
| GB201603291D0 (en) * | 2016-02-25 | 2016-04-13 | Binding Site Group The Ltd | Antibodies |
| EP3602026B1 (en) * | 2017-03-30 | 2025-10-08 | 908 Devices Inc. | Microfluidic analysis of biological samples |
-
2020
- 2020-01-30 JP JP2021544511A patent/JP2022519246A/ja active Pending
- 2020-01-30 KR KR1020217026598A patent/KR20210122803A/ko not_active Withdrawn
- 2020-01-30 WO PCT/US2020/015875 patent/WO2020160266A1/en not_active Ceased
- 2020-01-30 AU AU2020216172A patent/AU2020216172A1/en not_active Abandoned
- 2020-01-30 CA CA3126712A patent/CA3126712A1/en active Pending
- 2020-01-30 US US16/777,230 patent/US12169203B2/en active Active
- 2020-01-30 CN CN202080009967.XA patent/CN113646638B/zh not_active Expired - Fee Related
- 2020-01-30 EP EP20711357.2A patent/EP3918339A1/en not_active Withdrawn
- 2020-01-30 SG SG11202108033TA patent/SG11202108033TA/en unknown
- 2020-01-30 MX MX2021009267A patent/MX2021009267A/es unknown
- 2020-01-30 BR BR112021013716-5A patent/BR112021013716A2/pt not_active IP Right Cessation
-
2021
- 2021-07-18 IL IL284929A patent/IL284929A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020216172A1 (en) | 2021-08-05 |
| WO2020160266A1 (en) | 2020-08-06 |
| JP2022519246A (ja) | 2022-03-22 |
| US20200249241A1 (en) | 2020-08-06 |
| IL284929A (en) | 2021-09-30 |
| EP3918339A1 (en) | 2021-12-08 |
| SG11202108033TA (en) | 2021-08-30 |
| CN113646638B (zh) | 2024-05-24 |
| BR112021013716A2 (pt) | 2021-09-21 |
| US12169203B2 (en) | 2024-12-17 |
| MX2021009267A (es) | 2021-09-10 |
| CA3126712A1 (en) | 2020-08-06 |
| CN113646638A (zh) | 2021-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2476886C2 (ru) | Способ характеризации рекомбинантного поликлонального белка | |
| US12169203B2 (en) | Native microfluidic CE-MS analysis of antibody charge heterogeneity | |
| US20200017544A1 (en) | Detection and Quantification of Glycosylated Peptides | |
| JP7554312B2 (ja) | 液体クロマトグラフィー－質量分析を用いるタンパク質分析のシステムおよび方法 | |
| JP2025041777A (ja) | プロテインａクロマトグラフィー－エレクトロスプレーイオン化質量分析計 | |
| JP2023512521A (ja) | 天然液体クロマトグラフィ質量分析のためのプラットフォーム | |
| JP2021534408A (ja) | Ｄｅ ｎｏｖｏタンパク質シークエンシングのための方法 | |
| JP2020101538A5 (https=) | ||
| JP7695250B2 (ja) | 質量スペクトル分析においてシグナルを増強するためのアミノ酸の使用 | |
| US20240053359A1 (en) | Native microfluidic ce-ms analysis of antibody charge heterogeneity | |
| US20230043610A1 (en) | Native microfluidic ce-ms analysis of antibody charge heterogeneity | |
| WO2024020199A1 (en) | Native microfluidic ce-ms analysis of antibody charge heterogeneity | |
| CN114787630A (zh) | 用于抗体分析的疏水相互作用色谱法联用的天然质谱法 | |
| US20230018713A1 (en) | Characterization of proteins by anion-exchange chromatography mass spectrometry (aex-ms) | |
| Han et al. | Therapeutic monoclonal antibody intact mass analysis by capillary electrophoresis–mass spectrometry | |
| Han et al. | Capillary Electrophoresis–Mass Spectrometry (CE-MS) by Sheath–Flow Nanospray Interface and Its Use in Biopharmaceutical Applications | |
| CN118076890A (zh) | 通过阴离子交换色谱质谱(aex-ms)表征蛋白质 | |
| Richter et al. | Mass spectrometric analysis of protein species of biologics | |
| EA047087B1 (ru) | Мультиплексное количественное определение посттрансляционных модификаций белков с использованием тандемных массовых меток | |
| CN118765372A (zh) | 使用重肽进行序列变体分析 | |
| EA047025B1 (ru) | Использование аминокислот для усиления сигнала в масс-спектральном анализе | |
| EA046855B1 (ru) | Онлайн-хроматография и масс-спектрометр с ионизацией электрораспылением | |
| WO2019126614A1 (en) | Antibody peptide mapping and characterization using an erlic-ms/ms method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20210820 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20241011 Patent event code: PE09021S01D |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20241211 |
|
| WITB | Written withdrawal of application |